House Judiciary Chairman Jerrold Nadler (D-NY) delivered the following opening statement at a Subcommittee on Antitrust, Commercial, and Administrative Law hearing on “Oversight of Bankruptcy Law and Legislative Proposals”: “I thank the Chair for holding today’s hearing—the first hearing in the 116th Congress on the very important subject of bankruptcy reform. “The Bankruptcy Code, either directly... Read more »
Committee will investigate the rise and use of market power online and assess the adequacy of existing antitrust laws and current enforcement levels Today, the House Judiciary Committee announced a bipartisan investigation into competition in digital markets. The investigation will include a series of hearings held by the Subcommittee on Antitrust, Commercial and Administrative Law on the rise of ... Read more »
Today, the House Judiciary Committee unanimously passed four bills to address prescription drug pricing, including H.R. 965, the CREATES Act; H.R. 2375, the Preserve Access to Affordable Generics and Biosimilars Act; H.R. 2374, the Stop STALLING Act; and H.R. 2376, the Prescription Pricing for the People Act of 2019. This markup is part of the first phase of the Committee’s agenda to lower the soa... Read more »
Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) delivered the following opening statement for the markup of H.R. 2374, the Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (Stop STALLING Act): “H.R. 2374, the ‘Stop STALLING Act,’ takes an important step toward lowering drug prices and increasing competition in health care markets. It does t... Read more »
Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) delivered the following opening statement for the markup of H.R. 2376, the Prescription Pricing for the People Act of 2019: “H.R. 2376, the ‘Prescription Pricing for the People Act of 2019,’ would require the Federal Trade Commission to conduct a comprehensive report on the state of competition in the drug supply chain. “In particular... Read more »
Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) delivered the following opening statement for the markup of H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples Act of 2019 (CREATES Act): “H.R. 965, the ‘Creating and Restoring Equal Access to Equivalent Samples Act of 2019,’ or the ‘CREATES Act,’ is bipartisan legislation that would substantially lower drug price... Read more »
Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) delivered the following opening statement for the markup of H.R. 2375, the Preserve Access to Affordable Generics and Biosimilars Act: “H.R. 2375, the ‘Preserve Access to Affordable Generics and Biosimilars Act’ is one of a series of bipartisan measures that we are considering today to address the critical need to lower the soaring co... Read more »
On April 30, 2019 at 2pm, the House Judiciary Committee will consider four bills to address prescription drug pricing, including H.R. 965, the CREATES Act; H.R. 2375, the Preserve Access to Affordable Generics and Biosimilars Act; H.R. 2374, the Stop STALLING Act; and H.R. 2376, the Prescription Pricing for the People Act of 2019. Date: April 30, 2019 Time: 2:00 p.m. Location: 2141 Rayburn House O... Read more »
Today, House Judiciary Committee Chairman Jerrold Nadler (D-NY) and Ranking Member Doug Collins (R-GA) introduced H.R. 2375, the bipartisan Preserve Access to Affordable Generics and Biosimilars Act. This legislation strengthens the Federal Trade Commission’s (FTC) ability to challenge settlement agreements between large brand drug companies and generic drug companies in court, which will help low... Read more »
Washington, D.C. — Reps. Jerrold Nadler (D-N.Y.), Chairman of the House Judiciary Committee and Doug Collins (R-Ga.), Ranking Member of the House Judiciary Committee, today introduced the Prescription Pricing for the People Act of 2019. The legislation requires the Federal Trade Commission (FTC) to study pharmacy benefits managers (PBMs) and how their actions are affecting patients and local pharm... Read more »
